CD55 Antibody (BRIC 216): sc-59092

CD55 Antibody (BRIC 216) is a mouse monoclonal IgG1 antibody that recognizes CD55 in mouse, rat, and human samples through western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). CD55, also known as decay accelerating factor (DAF), is a glycosylphosphatidylinositol (GPI)-anchored single-chain glycoprotein that plays a crucial role in regulating the complement system for immune defense. By inhibiting the formation of the C3 convertase enzyme complex, CD55 prevents complement cascade amplification, protecting cells from complement-mediated lysis and membrane attack complex formation. This protective function is particularly important in tissues exposed to serum, as CD55 is expressed on various hematopoietic and non-hematopoietic cells. CD55′s ability to modulate immune response highlights CD55′s significance in maintaining cellular integrity and preventing unwanted tissue damage during immune reactions. Anti-CD55 antibody (BRIC 216) serves as an invaluable tool for researchers studying complement regulation and its implications in various diseases, including autoimmune disorders and transplant rejection.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD55 Antibody (BRIC 216) References:

1. The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias.  |  Ruiz-Argüelles, A. and Llorente, L. 2007. Autoimmun Rev. 6: 155-61. PMID: 17289551
2. Expression of complement regulatory proteins CD55, CD59, CD35, and CD46 in rheumatoid arthritis.  |  Piccoli, AK., et al. 2011. Rev Bras Reumatol. 51: 503-10. PMID: 21953001
3. Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.  |  Kwon, YC., et al. 2016. J Immunol. 197: 1127-36. PMID: 27357152
4. CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.  |  Saygin, C., et al. 2017. J Exp Med. 214: 2715-2732. PMID: 28838952
5. Novel CD55 Mutation Associated With Severe Small Bowel Ulceration Mimicking Inflammatory Bowel Disease in a Pair of Siblings.  |  Chongsrisawat, V., et al. 2022. Inflamm Bowel Dis. 28: 1458-1461. PMID: 35134932
6. Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59.  |  Brennan, K., et al. 2022. Cells. 11: PMID: 36359760
7. Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids.  |  Gaykema, LH., et al. 2022. Front Immunol. 13: 1058763. PMID: 36713440
8. Therapeutic hyperthermia regulates complement C3 activation and suppresses tumor development through HSPA5/NFκB/CD55 pathway in nasopharyngeal carcinoma.  |  Chen, C., et al. 2023. Clin Exp Immunol. 213: 221-234. PMID: 37249005
9. Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20.  |  Lee, SM., et al. 2023. Sci Rep. 13: 18275. PMID: 37880350
10. SARS-CoV-2 hijacks host CD55, CD59 and factor H to impair antibody-dependent complement-mediated lysis.  |  Gebetsberger, L., et al. 2024. Emerg Microbes Infect. 13: 2417868. PMID: 39435487

The preferred CD55 antibody is CD55 Antibody (NaM16-4D3): sc-51733.